Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Symtuza

Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13

HOS-138486 · Präparat HOS-098200

12 ANTIMALARIALS Artemether/Lumefantrine Based on theoretical considerations Symtuza and DRV/COBI is expected to increase artemether/lumefantrine can be lumefantrine plasma used without dose adjustments; concentrations. however, due to the increase in (CYP3A inhibition) lumefantrine exposure, the combination should be used with caution. ANTIMYCOBACTERIALS Rifampicin Based on theoretical considerations The combination of rifampicin rifampicin is expected to decrease and Symtuza is contraindicated darunavir and/or cobicistat and/or (see section 4.3). tenofovir alafenamide plasma concentrations. (CYP3A and/or P-gp induction) Rifabutin Based on theoretical considerations Co-administration of Symtuza Rifapentine these antimycobacterials are with rifabutin and rifapentine is expected to decrease darunavir not recommended. If the and/or cobicistat and/or tenofovir combination is needed, the alafenamide plasma recommended dose of rifabutin is concentrations. 150 mg 3 times per week on set (CYP3A and/or P-gp induction) days (for example Monday-Wednesday-Friday). Increased monitoring for rifabutin associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. Further dose reduction of rifabutin has not been studied. It should be kept in mind that the twice weekly dose of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure. Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV infected patients.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lumefantrine (HOS-114826) artemether (HOS-116383) rifabutin (HOS-086262) rifapentine (HOS-116386)